RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study

Background: Severe acute respiratory syndrome coronavirus 2 (SARS−CoV−2) infections and the resulting disease, coronavirus disease 2019 (COVID−19), have spread to millions of people globally. Multiple vaccine candidates are under development, but no vaccine is currently available. Methods: Healthy a...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :medRxiv
Главные авторы: Walsh, Edward E., Frenck, Robert, Falsey, Ann R., Kitchin, Nicholas, Absalon, Judith, Gurtman, Alejandra, Lockhart, Stephen, Neuzil, Kathleen, Mulligan, Mark J, Bailey, Ruth, Swanson, Kena A, Li, Ping, Koury, Kenneth, Kalina, Warren, Cooper, David, Fontes-Garfias, Camila, Shi, Pei-Yong, Türeci, Özlem, Thompkins, Kristin R, Lyke, Kirsten E., Raabe, Vanessa, Dormitzer, Philip R, Jansen, Kathrin U, Sahin, Uğur, Gruber, William C.
Формат: Artigo
Язык:Inglês
Опубликовано: Cold Spring Harbor Laboratory 2020
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7444302/
https://ncbi.nlm.nih.gov/pubmed/32839784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1101/2020.08.17.20176651
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы